This decommissioned ERA site remains active temporarily to support our final migration steps to https://ualberta.scholaris.ca, ERA's new home. All new collections and items, including Spring 2025 theses, are at that site. For assistance, please contact erahelp@ualberta.ca.
Search
Skip to Search Results-
Development of novel compounds for the molecular imaging of hypoxia: 18F-labeled nitroimidazoles and hypoxia inducible factor 1 alpha (HIF-1a)-targeting compounds
DownloadSpring 2023
Imaging of hypoxia has been previously achieved using positron emission tomography (PET) with radiotracers such as [18F]fluoroazomycin arabinoside ([18F]FAZA) [1] or [18F]fluoromisonidazole ([18F]FMISO) [2]. These typical nitroimidazole containing compounds are reductively trapped in hypoxic...
-
Evaluation of Hypoxia Induced Regulation of Nucleoside and Amino Acid Membrane Transporters in Breast Cancer
DownloadSpring 2020
Positron Emission Tomography (PET) utilizes radioactively tagged molecules to identify cancerous tissue. In most cases, membrane transporters control entry of these molecules into human cancer cells. Hypoxia-inducible factor (HIF)-1 is the master homeostatic regulator during hypoxia in human...
-
Pre-clinical Evaluation of Iodoazomycin Arabinofuranoside (IAZA) and Fluoroazomycin Arabinofuranoside (FAZA) as Hypoxia-targeting Therapeutic Agents in a Head and Neck Cancer Model
DownloadSpring 2022
Tumour hypoxia is a well-recognized clinical problem that promotes resistance to anti-cancer treatment (chemotherapy, radiotherapy, and immunotherapy), increases rates of recurrent disease, and ultimately leads to poor patient outcome. Eradication of hypoxic tumours is, therefore, essential for...